Please login first
CRISPR-Cas Genome Edition: Bioethical and Regulatory Issues
1  Department of Public Law, University of the Basque Country UPV/EHU, 48940, Leioa, Biscay, Spain

https://doi.org/10.3390/mol2net-06-08954 (registering DOI)
Abstract:

In a previous work we discussed about the concerns emerging worlwide related to the now widespread use of CRISPR-Cas genome editions' technique. This technique is a very important tool in molecular biology now a days and is called to become an important tool in Molecular Pharmacology, Personalized Medicines, and Synthetic Biology. In Drug Discovery and Medicinal Chemistry and Chemical Biology may be used for resistance-selection studies of antimicrobial compounds; research on druggability of new compounds, or implementation of new laboratory animal models for assay of new compounds. The implications for Biotechnology an dSynthetic Biology are more bizarre. Totally new compounds not existing in nature may be created in a very fast-track way. In our previouspaper, we given an state-of-art discussion of literature with examples of CRISPR uses in chemical biology. We also discussed legal and ethical concerns still preset nowadays.

Ref: A. Duardo-Sanchez. CRISPR-Cas in Medicinal Chemistry: Applications and Regulatory Concerns Curr Top Med Chem, 2017;17(30):3308-3315.

Keywords: CRISPR-Cas; Drug discovery; Gene editing legal issues; Synthetic organisms

 
 
Top